增强免疫组化和原位杂交方法检测非小细胞肺癌的ALK重排的临床可行性

摘要

Background and objective Besides epidermal growth factor receptor (EGFR) mutation, the non-small cell lung cancer (NSCLC) of anaplastic lymphoma kinase (ALK) rearrangement becomes another important clinical subtype. A speciifc and high-sensitive and economical detection way is convenience for identiifcation of ALK positive NSCLC quickly and accurately. So the objective of our research is to detect ALK rearrangement in 172 cases of NSCLC by using enhancing immunohistochemical way (ventana-IHC, V-IHC). Methods ALK rearrangement in 172 NSCLC samples was detected by us-ing V-IHC, and positive staining cases were further veriifed by lfuorescence in situ hybridization (FISH). Results Among 172 NSCLC cases, there were 12 positive staining. hTe positive results were conifrmed by FISH and 11 cases were FISH positive. hTe overall concordance between V-IHC and FISH is 91.7%(11/12). Conclusion hTe V-IHC method is a reliable method for ALK arrangement and could be used in clinical screen and diagnosis.%背景与目的继表皮生长因子（epidermal growth factor receptor, EGFR）突变之后，间变性淋巴瘤激酶（anaplastic lymphoma kinase, ALK）基因重排的非小细胞肺癌（non-small cell lung cancer, NSCLC）已经成为了肺癌的又一重要的临床分型。在临床上需要选择一种特异，灵敏并且价廉的方法准确快速地找到ALK阳性的NSCLC患者。为此本研究探讨增强免疫组化法（ventana-IHC, V-IHC）检测ALK重排的临床可行性。方法利用V-IHC检测172例NSCLC患者ALK重排，阳性患者以荧光原位杂交法（lfuorescence in situ hybridization, FISH）验证。结果172例NSCLC患者中有12例为ALK阳性，经过FISH验证，11例患者为阳性，符合率为91.7%。结论在NSCLC中，V-IHC是ALK检测切实可行的方法，适用于ALK重排的NSCLC的筛查和诊断。